TY - JOUR T1 - Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis JF - J Viral Hepat Y1 - 2020 A1 - Boyle, A A1 - Marra, F A1 - Peters, E A1 - et, al VL - 27 SP - 371-375 IS - 4 ER -